Host Serine Proteases: A Potential Targeted Therapy for COVID-19 and Influenza

Yalda Rahbar Saadat†, Seyed Mahdi Hosseiniyan Khatibi†, Sepideh Zununi Vahed* and Mohammadreza Ardalan*

Kidney Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

The ongoing pandemic illustrates limited therapeutic options for controlling SARS-CoV-2 infections, calling a need for additional therapeutic targets. The viral spike S glycoprotein binds to the human receptor angiotensin-converting enzyme 2 (ACE2) and then is activated by the host proteases. Based on the accessibility of the cellular proteases needed for SARS-S activation, SARS-CoV-2 entrance and activation can be mediated by endosomal (such as cathepsin L) and non-endosomal pathways. Evidence indicates that in the non-endosomal pathway, the viral S protein is cleaved by the furin enzyme in infected host cells. To help the virus enter efficiently, the S protein is further activated by the serine protease 2 (TMPRSS2), provided that the S has been cleaved by furin previously. In this review, important roles for host proteases within host cells will be outlined in SARS-CoV-2 infection and antiviral therapeutic strategies will be highlighted. Although there are at least five highly effective vaccines at this time, the appearance of the new viral mutations demands the development of therapeutic agents. Targeted inhibition of host proteases can be used as a therapeutic approach for viral infection.

Keywords: coronavirus, COVID-19, human proteases, TMPRSS2, furin, influenza

HIGHLIGHTS

- Furin and TMPRSS2 mediate SARS-corona virus infection, SARS-CoV-2, and influenza entry into the human cells.
- As a causative factor, TMPRSS2 exerts more severe outcomes for COVID-19.
- Targeted inhibition of TMPRSS2 and furin may be used as a therapeutic approach for COVID-19.
- Bromhexine hydrochloride may be an effective therapeutic drug for COVID-19.

INTRODUCTION

Over the last 2 decades, several outbreaks of coronaviruses (CoVs) have received worldwide attention since they were responsible for the SARS (severe acute respiratory syndrome coronavirus) in China (2002–2003) and the MERS-CoV (Middle East respiratory syndrome) in Saudi Arabia (2012). Currently, the world is struggling with the novel CoV (SARS-CoV-2), initially recognized in China in late 2019. Since its discovery, SARS-CoV-2 has spread globally and its epidemic disease (COVID-19) has claimed thousands of lives. To date, the high number of infected cases with severe respiratory
illnesses and viral pneumonia is observed as a risky and rapid human-to-human transmission occurrence (Ashour et al., 2020).

Receptor recognition is a significant element of SARS-CoV-2 infection, pathogenesis, determining host range, and a therapeutic target (Wang et al., 2020a; Shang et al., 2020). SARS-CoV-2-spike S protein (SARS-CoV-2-S), similar to SARS-CoV, exploits human angiotensin-converting enzyme 2 (ACE2) for its entry. Using the same entrance receptor as SARS-CoV, the same set of cells can be targeted and infected by SARS-CoV-2 (Rabi et al., 2020).

In situ analysis of different tissues has revealed top primary vulnerable cells to SARS-CoV-2, including the AT2 lung cells and macrophages, adrenal gland stromal cells, cardiomyocytes, thyroid, ovary, and stromal testis cells. Some other cells are less likely to be the main targets of SARS-CoV-2 (including enterocytes, cholangiocytes, and the kidney proximal tubule cells) (Zhou et al., 2020).

Although binding to host cells is the initial step of infection, virus entrance necessities the cleavage of S protein via host proteases including cell surface transmembrane protease/serine (TMPRSS) proteases, cathepsins, furin, elastase, factor Xa, and trypsin (Lambertz et al., 2019; Ji et al., 2020; Liu et al., 2020; Luan et al., 2020). Evidence suggests that numerous respiratory viruses hijack host proteases in order to enhance their spread in the host body. Based on the accessibility of cellular proteases needed for SARS-S activation, SARS-CoV-2 entrance and activation can be mediated by two distinct ways; 1) endocytosis and the cutting of the SARS-CoV-2 spike by cathepsin L in endosomes (Glowacka et al., 2011; Shirato et al., 2013) and 2) by TMPRSS2 and furin provided that it is co-expressed with ACE2 on the target cells’ surface (Heurich et al., 2014). This binding process entails several conformational alternations in the viral envelope glycoproteins (Shen et al., 2017), resulting in virion internalization. Since SARS-CoV-2 employs host proteases as its entrance activators, their inhibitors may exert therapeutic benefits against COVID-19 (Bestle et al., 2020a) and SARS-CoV infections (Shrimp et al., 2020). In the present review, we will highlight the recent updates on the functional role of host proteases, specially TMPRSS2 and furin in viral infection and discuss the possible interventions for inhibiting these enzymes.

**FIGURE 1 |** Architecture of SARS-CoV-2 virus (A) SARS-CoV-2 schematic (B) spike protein, (C) alignment of SARS-CoV-2, MERS-CoV, and SARS-CoV sequences in protease cleavage sites S1/S2 and S2. A furin cleavage motif (RRAR) only exists in the SARS-CoV-2 spike. Trypsin, furin, and TMPRSS2 and 4 can cleave the S1/S2 site within the receptor binding domain (RBD) of S protein generating the optimal conformation for viral binding to the host ACE2 receptor. The viral membrane fusion with the host membrane S2 domain can be cleaved by TMPRSS 2 and 4. Panel C is adapted from Luan et al. (2020).
SARS-CoV-2 VIRION

The SARS-CoV-2 virion is a non-segmented RNA-positive virus (Zumla et al., 2016). Its genome encodes nucleocapsid (N), membrane (M), envelope (E), and spike (S) structural proteins. The M and E proteins are located among the spike proteins in the viral envelope (Figure 1A). The virion has a nucleocapsid composed of a single-stranded and positive-sense RNA in a size of 29.9 kb and highly immunogenic phosphorylated N-protein that is covered by the S and the hemagglutinin-esterase (HE) spike proteins, buried inside the phospholipid bilayers (Wu et al., 2020a; Jin et al., 2020).

The SARS-CoV-2 genome has a highly similar identity to the human SARS-CoV (80%) (Matsuyama et al., 2010), hence, they have analogous pathogenesis and biochemical interactions. The S protein eases receptor-binding and viral entrance into the target cells by the fusion of the viral and host cell membranes; hence, it can determine the host range (Heurich et al., 2014; Hoffmann et al., 2020a). Moreover, the spike S is the common target for vaccines and neutralizing antibodies. Spike protein has two functional subunits; the surface unit (S1) and S2 (Figure 1B). The S1 recognizes a cellular receptor by a receptor-binding domain (RBD), mediating viral attachment to the host ACE2. The S2 subunit has other basic features needed for the fusion of the viral and cell membranes. The high cleavable properties of the S1/S2 cleavage site of SARS-2-S are attributed to its multi-basic structure (several arginine residues).

In the CoVs, the RBD can be in a standing-up or a lying-down state. The first state permits receptor binding; however, the second state does not (Yuan et al., 2017). SARS-CoV-2-S is frequently in the lying-down state in comparison to SARS-CoV; consequently, despite having high affinity, it is less available to the ACE2. This difference results in a lower or comparable receptor binding affinity for the SARS-CoV-2 whole spike (Shang et al., 2020). The SARS-CoV-2’ RBD has a greater affinity to bind to the ACE2 than SARS-CoV; conversely, the whole spike glycoprotein of SARS-CoV-2 cannot bind to human ACE2 stronger than SARS-CoV’ spike (Shang et al., 2020). To preserve its RBD less accessible while retaining its high infectivity, SARS-CoV-2 depends on a second strategy; the activation of host proteases (Figure 1C).

ENTRY AND PRIMING OF SARS-CoV-2 BY THE HOST PROTEASES

The high binding affinity of SARS-CoV-2 to the human receptor is one reason why it is more hostile than SARS-CoV (Wu et al., 2020a; Lu et al., 2020). The viral infectivity highly relies on the cleavage of the S protein by the cell proteases that happens during different steps in the viral life cycle (Heurich et al., 2014). Two cellular proteolytic systems were utilized by SARS-CoV in order to guarantee the adequate processing of viral S protein (Figure 2). The SARS-CoV-2 interaction with the human cells is similar to SARS-CoV (Ragia and Manolopoulos, 2020). The proteolysis of the two peptide bonds (i.e., Arg685-Ser686) results in the so-called S1 and S2 subunits separation and the subsequent activation/priming of the S protein of SARS-CoV-2 (Fuentes-Prior, 2021). The presence of receptor-binding domain (RBD) in the N-terminal domain (NTD) of the S1 subunit causes direct binding to the peptidase domain of ACE2, whereas, the C-terminal of the S2 subunit is responsible for its attachment viral envelope after proteolysis at the S1/S2 site and eventually leads to its fusion with the host cell membrane (Benton et al.,...
The binding of the SARS-S to the ACE2 can promote the virions endocytosis. It is reported that Cathepsin L cleaves the S protein of SARS-CoV-2 functionally and promotes viral entry (Zhao et al., 2021). SARS-S/ACE2 complex generates conformational changes in SARS-S, which in turn, may raise the sensitivity of the spike to proteolytic enzymes. Inside the endosome, Cathepsin L, a pH-dependent endosomal or lysosomal protease, facilitates the cleavage of SARS-S and activates the S protein for fusion within the endosomal membrane. During endosome maturation, the low pH of the endosomal environment activates the re-arrangement of HA that exposes the viral fusion peptide into the endosomal membrane (Shen et al., 2017; Simmons et al., 2013; Iwata-Yoshikawa et al., 2019a), exerting an important role in their spread (Iwata-Yoshikawa et al., 2019b). Furthermore, the TMPRSS2 might stimulate viral pathogenesis and spread via activating spike S for virus-cell and cell-cell fusion and neutralizing antibodies that decrease viral recognition (Glowacka et al., 2011).

CATHEPSINS

Human cathepsins are endosomal proteases with broad proteolytic activity in acidic pH. Cathepsins activation in lysosomes may exert an important role in SARS-CoV and MERS-CoV entry via endocytosis (Sahebnasagh et al., 2020). Lysosomal cathepsin L cleaves peptide bonds with hydrophobic residues in the P3 position and aromatic residues in the P2 position (Vargas-Alarcón et al., 2020). Cathepsin L incorporates in glycoprotein processing of SARS-CoV and Ebola (Pišlar et al., 2020; Vargas-Alarcón et al., 2020). Recent investigations assessed cathepsins’ role in SARS-CoV-2 entry. Further, the role of cathepsin L is highlighted in virion entry into human embryonic kidney 293 cells expressing ACE2; however, CA-074 did not significantly affect SARS-CoV-2 entry (Pišlar et al., 2020).

NEUTROPHIL ELASTASE

Neutrophil elastase mediates acute lung injury through increasing inflammatory reactions (e.g., increasing vascular permeability, induction of pro-inflammatory cytokines such as IL-8 and IL-6 secretion by neutrophil vesicles, and conversion of pro-IL-1β to IL-1β) (Bai et al., 2020). Under normal conditions, the NE’s function is regulated by the inhibitors of endogenous protease. Nevertheless, under pathophysiological conditions, neutrophil oxidants inactivate the aforementioned inhibitors which result in hydrolyzing the host extracellular matrix proteins such as collagen-IV as well as elastin and subsequent damage to the endothelial barrier and infiltration into the bronchoalveolar space (Korkmaz et al., 2020; Thierry, 2020).

PLASMIN

Pathogens, especially viruses, convert plasminogen to plasmin in order to cleave surface proteins and subsequently can evade the
immune system or infect host cells (Medcalf et al., 2020). Plasmin can cleave new furin sites in SARS-CoV S protein which in turn results in increased viral infectivity (Ji et al., 2020). In addition to the contribution of early stages of a viral infection, plasmin can provoke cytokine production and stimulate inflammation via factor XII/bradykinin which subsequently can increase edema (Medcalf et al., 2020). The elevated levels of plasmin (ogen) were observed in COVID-19 patients (Ji et al., 2020). Plasmin can cleave hyaline membranes (consist of a fibrin network combined with serum proteins and cellular debris, acts as barriers to gas exchange in the alveoli), which is considered as a histopathological hallmark of acute respiratory distress syndrome (ARDS) induced by SARS-CoV-2. In patients affected by the ARDS, bronchoalveolar lavage samples showed elevated levels of active plasmin and plasminogen (Henry et al., 2020).

THE FUNCTIONAL ROLE OF HOST PROTEASES IN SARS-COV-2 INFECTION

The Role of Furin in SARS-CoV-2 Infection

Bioinformatics analysis on the SARS-CoV-2-S sequences has anticipated a novel polybasic furin cleavage site containing an insertion of amino acid residues (PRRA–) between S1 and S2 subunits (Figure 1C). Based on the genomic characteristics of SARS-CoV-2, furin can cleave the viral spike protein at that site and activate it (Mallapaty, 2020). Coutard et al. identified a furin-like cutting site in the SARS-CoV-2-S which is not available in other SARS-like CoVs such as Pangolin, Bat-CoV, and SARS-CoV-1. MERS has a pseudo-furin-binding site (Coutard et al., 2020; Vankadari, 2020). Likewise, Vankadari found that structurally, furin interacts with the SARS-CoV-2-S that highlighted the mechanism of viral host cell entry (Vankadari, 2020).

In lung cells that highly express furin and fail to express strong cathepsin L levels, pre-cleavage of the S proteins by furin is needed for consequent activation of spike protein by TMPRSS2 in both MERS-CoV and SARS-CoV-2 (Hoffmann et al., 2020b). In order to initiate the membrane fusion of viral and human cells along with the passage of viral genome into the cytoplasm of the host cell, viral spike S glycoprotein needs to be sequentially cleaved at S1/S2 and S2’ sites. Furin cleaves the S1/S2 site, while the TMPRSS2 processes at the S2’ site, and these enzymes cannot compensate for each other. Finally, at the Golgi or endoplasmic reticulum compartment, nascent viruses are assembled and released from the infected cells by exocytosis (Hoffmann et al., 2018). Preactivation of furin permits SARS-CoV-2 to be less reliant on host cells, improving its entry into some target cells that relatively express low levels of lysosomal cathepsins and/or TMPRSS2 (Shulla et al., 2020).

It is revealed that the furin enzyme is expressed in other potential target organs of the coronavirus such as the intestine, colon, ileum, rectum, heart, and oral mucosa tissues (Dittmann et al., 2015; Mei et al., 2020). The furin universal expression in some tissues and organs may be an explanation for the high pathogenicity and transmissibility of SARS-CoV-2 (Wang et al., 2020a). Therefore, in the course of SARS-CoV-2 infection, the presence of furin may result in some clinical symptoms (Dittmann et al., 2015), for example, the furin-mediated entrance of SARS-CoV-2 into the cardiomyocyte may clarify the cardiac injury in patients with COVID-19 (Dittmann et al., 2015). Moreover, the furin protease activity in the oral mucosa tissues makes them susceptible to SARS-CoV-2 and may be associated with oral symptoms in COVID-19 like taste blindness and dry mouth (Mei et al., 2020).

The Functional Role of TMPRSS2 in Viral Infection

Accumulating evidence reveals that SARS-CoV-2 and relevant viruses such as MERS-CoV, influenza A virus (FLUAV), and SARS-CoV require TMPRSS2 activity as a host cell factor for their spread (Hoffmann et al., 2020a; Kim J et al., 2020). Moreover, it is reported that the VeroE6 cell line, expressing TMPRSS2, is very vulnerable to SARS-CoV-2 infection; indicating that similar to MERS-CoV and SARS-CoV, SARS-CoV-2 infection is boosted by TMPRSS2 (Matsuyama et al., 2020). Furthermore, both lysosomal cathepsins and TMPRSS2 have accumulative effects with a calcium-dependent proprotein/prohormone convertase (furin) on activating the entrance of SARS-CoV-2 in some cells such as lungs. (Shang et al., 2020).

TMPRSS2, by cleaving the SARS-CoV-2-S facilitates virus entrance and activation (Hoffmann et al., 2020a). The co-expression of TMPRSS2 in ACE2-positive lung cells suggests that it exerts a critical role in the spread of the virus in the human respiratory tract (Heurich et al., 2014).

TMPRSS2 eases the infection of SARS-CoV by two independent mechanisms; a) by ACE2 cleavage that enhances the viral entry and stimulates viral uptake by cathepsin L-dependent entry, not activating SARS-S for entry (Figure 2A), b) by SARS-S cleavage at the host cell surface that activates the spike protein for membrane fusion (Figure 2B) (Heurich et al., 2014). Two amino acid residues (arginine and lysine) within the ACE2 (697–716 and 652–659) are critical for TMPRSS2 and the metalloprotease ADAM17, respectively. These enzymes compete together for the ACE2 cleavage; however, only TMPRSS2-mediated-ACE2 cleavage stimulates SARS-S-driven entry (Shulla et al., 2011; Heurich et al., 2014). The ADAM17 eases the ACE2 shedding into the extracellular space and stimulates SARS-CoV uptake into the host cells (Figure 2B). Additionally, ADAM17 facilitates the release of the TNF-α (tumor necrosis factor-α) and IL-6 receptors. The TNF-α exerts autocrine and paracrine function and TNF-α/its receptor signaling elevates ADAM17 activity. Viral infection and endocytosed SARS-CoV-2 spike proteins also elevate ADAM17 activity. An increased ACE2 shedding by ADAM17 leads to the down-regulation of ACE2 that increases the angiotensin II levels, resulting in further rises in ADAM17 activity (Gheblawi et al., 2020).

Different residues (R667 and R797) in SARS-S control the TMPRSS2-mediated S activation indicating that these procedures are more complex than initially appreciated (Reinke et al., 2017). Glowacka et al. concluded that based on the location of the TMPRSS2, the processing of the SARS-S cleavage by host cell
TMPRSS2 can have different results. In the secretory pathway of infected cells, when the TMPRSS2 is co-expressed with SARS-S in the same cell, spike cleavage leads to the shedding of SARS-S into the supernatants, and as antibody decoys, the S protein fragments inhibit antibody-mediated neutralization (Glowacka et al., 2011).

Evidence proposes that the TMPRSS2 may control the function of mitochondria through the estrogen-related receptor-α (ERR-α) (Xu et al., 2018). ERR-α, a nuclear receptor, along with its coactivator peroxisome proliferator-activated receptor-γ coactivator-1α (PGC-1α) regulate mitochondrial functions and energy homeostasis at the transcriptional level (Xu et al., 2018). Mitochondrial hijacking by SARS-2 may be one of the underlying mechanisms leading to COVID-19. Few human genes including a subunit of ubiquitin-protein ligase complex (FBXO21) and mitochondrial ubiquitin specific peptidase 30 (USP30) appear to be targeted by viral RNA (Pasquier and Robichon, 2020). During infection, viral RNAs can be translocated into the mitochondria to hijack and utilize host mitochondria. By modifying ubiquitination and impacting mitochondrial function, SARS-CoV-2 can repress host immunity in COVID-19 cases via different mechanisms. One possible viral mechanism can be mediated by regulating the host USP30. USP30 regulates the mitochondrial homeostasis and dynamics (fusion and fission). The presence of 20 nucleotides in open-reading frame 3a (ORF3a) of SARS-CoV-2 can target a sequence in mitochondrial USP30 transcripts (Pasquier and Robichon, 2020). Utilizing the host mitochondria by viral ORFs can result in mitochondrial DNA (mtDNA) release in the cytoplasm that activates the mtDNA-induced inflammation and represses both innate and adaptive immunity. Finally, the mitochondrial collapsing by virus results in the death of the infected cells (Singh et al., 2020).

The TMPRSS2 Gene
The TMPRSS2 gene consists of 14 exons and 13 introns (44 kb in length) and is located on human chromosome 21. It is more expressed in prostate cancer cells (Paolini-Giacobino et al., 1997). One of the important characteristics of the TMPRSS2 gene is located at position –148 with several 15-bp androgen response elements (AREs) at the upstream of the transcription start origin (Lin et al., 1999; Aafar et al., 2001). In prostate cancer cells, androgenic hormones up-regulate the TMPRSS2 gene which probably is mediated by the androgen receptor (Antalis et al., 2011; Shen et al., 2017; Ashour et al., 2020). Studies in knock-out murine models revealed that these mice are resistant to the spread and pathogenesis of some subtypes of the FLUAV. As mentioned earlier, TMPRSS2 can be regulated by androgen and its receptor (Chen et al., 2019) and the presence of AREs on the promoter of the TMPRSS2 gene may be the underlying cause of the severity and higher mortality of COVID-19 in men (Zununi Vahed et al., 2020). Moreover, the promoter of the human TMPRSS2 gene has a guanine-rich region forming G-quadruplex secondary structures that can block or reduce TMPRSS2 transcription in the presence of potassium ions (Shen et al., 2020). Furthermore, studies regarding the TMPRSS2 gene polymorphisms that cause TMPRSS2 gene overexpression in humans, showed its association with severe influenza (Hoffmann et al., 2018). It is demonstrated that genetic variation in TMPRSS2 including two identified SNP in TMPRSS2 (rs383510 and rs2070788) had a strong correlation with the A (H7N9) influenza susceptibility (Cheng et al., 2015).

Complete computational analyses indicated that functional single nucleotide polymorphisms of TMPRSS2 gene and epigenetic mechanisms play important roles in the diverse susceptibility of different populations to SARS-CoV-2 (Paniri et al., 2020). TMPRSS2 genetic variants including rs383510, rs2070788 37, rs469390, and rs464397 strongly increase the TMPRSS2 expression in lung tissue, where these variants at higher frequencies are present in European and American populations than the Asian populations. This result suggests these populations may be quite more vulnerable to SARS-CoV-2 infection (Irham et al., 2020).

TMPRSS2 Expression in Different Cells
Remarkably, the TMPRSS2 has a highly variable expression in humans and its expression may be positively associated with COVID-19 severity. The TMPRSS2 is mainly expressed in the epithelium cells of the prostate and has a vital role in its carcinogenesis (Lucas et al., 2008). Matsuyama et al. (2010) indicated an interaction of the TMPRSS2-expressing cells with viral tropism and pathogenicity of SARS-CoV infection. The TMPRSS2 is also expressed in the lungs (Bertram et al., 2012), digestive tract, kidney, the cardiac endothelium proposing that these organs may be essential targets for SARS-CoV-2 infection (Bertram et al., 2012). Indeed, the COVID-19 clinical manifestations include complications from gastrointestinal symptoms, higher liver enzymes, acute kidney injury (AKI), and acute myocardial damage. It was approved that the expression of the ACE2 and the TMPRSS2 provides SARS-CoV-2 entrance on the ocular surface cells. Moreover, the co-express of the TMPRSS2 and the ACE2 in the prostate epithelial cells may be involved in more pathogenicity of COVID-19 disease in males than females (Song et al., 2020). The TMPRSS2 and TMPRSS4 promote virus entry into the intestinal cells by facilitating SARS-CoV-2 spike fusogenic activity (Zang et al., 2020).

Based on the different datasets of gene expression, it is found that the expression levels of the TMPRSS2 and the ACE2 are significantly higher in the nasal epithelium in comparison to saliva and blood, where their levels decrease in lower airway tissues. Significantly, the expression levels of these genes in the bronchial and nasal tissues are lower in children than adults. The result of this study indicates that the severity of COVID-19 between adults and children, in part, can be attributed to the different expression levels of the TMPRSS2 and the ACE2 in airways tissues (Saheb Sharif-Askari et al., 2020). Mechanisms that influence SARS-CoV-2 infectivity and clinical outcomes of COVID-19 are reported by analyzing the nasal airway transcriptome of children. In this study, it is found that the ACE2 expression is upregulated by interferon response to respiratory viruses. Moreover, the action of IL-13a upregulates the TMPRSS2 as a mucus secretory network gene (Sajuthi et al., 2020).
THERAPEUTIC STRATEGIES TO TARGET HOST PROTEASES FOR COVID-19

Unraveling the viral RBD features can open a new horizon to block the spike cleavage sites and develop protease inhibitors. Recent studies suggest that host proteases are vital for the activation of the SARS-CoV-2 in human epithelial cells, hence, they can be hopeful drug targets for the management of COVID-19 (Bestle et al., 2020a). Therapeutic inhibition of the TMPRSS2 and furin may be used as a therapeutic approach for

### TABLE 1 | A list of host protease inhibitors against COVID-19

| Targets/Inhibitors | Mechanism of action | Studied models | References |
|--------------------|---------------------|----------------|------------|
| **Furin protease inhibitors** | | | |
| MI-1851 | -Inhibits virus entry by preventing furin cleavage at S1/S2 site of S protein | *In vitro* | Bestle et al. (2020a) |
| Diminazene (an anti-parasitic drug) | -Inhibits SARS-CoV-2 replication | *In vitro* | Wu et al. (2020b) |
| Decanoyl-RVKR-chloromethylketone (CMK) | -Inhibits SARS-CoV-2 RNA transcription rather than virus entry. | *In vitro* | Cheng et al. (2020) |
| Naphthofluorescein | | | |
| TMPRSS2 protease inhibitors | | | |
| MI-432 | Inhibits virus entry by hindering TMPRSS2 cleavage at S2 site of S protein | *In vitro* | Meyer et al. (2013) |
| MI-1900 | -Inhibits virus entry by hindering TMPRSS2 cleavage at S2 site of S protein | *In vitro* | Bojkova (2020) |
| Aprotinin | -Prevents double-stranded RNA formation in SARS-CoV-2 infected cells | *In vitro* | Sahebnasagh et al. (2020) |
| Excavatolide M, Dictyosphaeric Acid A, Durumolide K, Schisphenin Ac, CYD (S)-Diphosphocholine (Citoline), 5-Methoxynorcarpin D, Polyphenol (-)-Epicatechin 3-O-(30-O-Methyl) Gallate, Curtisian L, Microcarpin, Geniposide, NPC306344, Isogemichalcone B | These compounds interact with the active site residues of TMPRSS2 and inhibit it | *In silico* | Rahman et al. (2020) |
| Nafamostat mesylate | Prevents S-glycoprotein activation by inhibiting TMPRSS2 | *Clinical trial* | Hoffmann et al. (2020a) |
| Camostat mesylate | -Decreases SARS-CoV-2 replication significantly | *In vitro* | Bestle et al. (2020a) |
| Cathepsin B and L inhibitors | Had no marked effect on virus entry | *Clinical trial* | Ansarin et al. (2020) |
| CA-074: an inhibitor of Cathepsin B | Reduced entry of SARS-CoV-2 S pseudovirions | *In vitro* | Sahebnasagh et al. (2020) |
| E64D: an endosomal cysteine proteases (CatB/L) inhibitor | Had no effect on virus replication in Calu-3 (human airway epithelial cells) | *In vitro* | Bestle et al. (2020a) |
| Dalbavancin | By preventing cathepsin L in the late endosome/lysosome represents an antiviral effect. | *In vitro* | Zhang (2020) |
| Teicoplanin: an inhibitor of Cathepsin L | Prevents HIV-1/2019-nCoV-S pseudoviruses entry in a dose-dependent manner | *In vitro* | Zhang (2020) |
| SID 26681509: an inhibitor of Cathepsin L | Reduced entry of SARS-CoV-2 S pseudovirions in 293/ hACE2 | *In vitro* | Sahebnasagh et al. (2020) |
| Other protease inhibitors | | | |
| BenHCl, an inhibitor of Factor Xa | Factor Xa could cleave the full-length recombinant S protein into S1 and S2 subunits, and this cleavage | | Du et al. (2007) |
| Rivaroxaban, apixaban, edoxaban, and betrixaban, inhibitors of Factor Xa | They present anti-inflammatory, antiviral, and anticoagulants effects | | Al-Horani (2020) |
COVID-19. A list of host proteases inhibitors is listed in Table 1. In the following section, we review the potential drugs or compounds that may alter the TMPRSS2 expression and activity.

**Modulating the Expression and Activity of TMPRSS2**

Besides SARS-COV, the TMPRSS2 is critical for viral spread of the H3N2 influenza A virus (IAV) and mono-basic H1N1 virus (Hatesuer et al., 2013) and also for the replication and pathogenesis of the H10 subtype of IAV in mice (Lambertz et al., 2019), where knock-out Tmprss2 mice were resistant to the virus. This subtype can also infect humans emphasizing the significance of the TMPRSS2 for drug development against multiple IAV subtypes (Lambertz et al., 2019). The TMPRSS2 can also activate HCV infection at the entry and post-binding stages and involve in the persistence, pathogenesis, and sensitivity of HCV infection (Nickols and Dervan, 2007). Since the TMPRSS2 is involved in other viral infections such as coronavirus (MERS-CoV, SARS-CoV, hCoV-EMC, and hCoV-229E) (Glowacka et al., 2011; Bertram et al., 2013; Gierer et al., 2013; Shirato et al., 2013), hepatitis C virus (Esumi et al., 2015), and influenza A virus (Shen et al., 2020), it would be an attractive alternative against a wide spectrum of respiratory viruses, especially SARS-CoV-2. Taken together, the TMPRSS2 is a target for antiviral therapy.

As we mentioned earlier, the AREs are involved in the TMPRSS2 expression and can be striking drug targets. A polyamide compound can bind to the ARE in the TMPRSS2 promoter and moderately repress its expression (Nickols and Dervan, 2007). Wang et al. (2020) by mining publicly available data on gene expression, identified the estrogen-related compounds including genistein, androgen receptor antagonist enzalutamide and estradiol can down-regulate the TMPRSS2. These reports suggest that the aforementioned drugs can be promising therapeutic candidates for the treatment of COVID-19. (Wang et al., 2020b).

The promoter of the human TMPRSS2 gene has a guanine-rich region forming G-quadruplex secondary structures that can block or reduce the TMPRSS2 transcription in the presence of potassium ions (Shen et al., 2020). Benzoxelenoxanthen analogs could significantly down-regulate the TMPRSS2 expression by stabilizing G-quadruplex structure and could prevent the growth and spread of influenza A virus in vitro (Shen et al., 2020). Therefore, the down-regulation of the TMPRSS2 mRNA through G-quadruplex structure stabilizers can be a promising strategy in developing novel small molecule drugs against SARS-CoV-2.

Antioxidants serve as regulators of the protease/antiprotease balance that can prevent viral infection. Antioxidants—the so-called free radical scavengers- are natural or man-made substances that can prevent or neutralize free radicals’ damage to cells. It has been elucidated that the master antioxidant transcriptional factor (Nrf2) could down-regulate the expression of the TMPRSS2 in prostate cancer cell lines, thus causing alternations in the protease/antiprotease components balance and subsequently, and result in protection against the respiratory infections (Meyer and Jaspers, 2015). The Nrf2 has a critical role in the reduction of oxidative stress; besides, it exerts beneficial effects in respiratory epithelial responses to respiratory viral infection. Various types of antioxidants are available nowadays. Sulforaphane (SFN) is a potent antioxidant belonging to the class of isothiocyanates, a sulfur-containing organic compound naturally found in cruciferous vegetables (e.g., cauliflower and broccoli). It may decrease oxidative stress and inflammation besides exerting antimicrobial effects. It has been shown that the beneficial effects of the SFN supplementation depend on promoting the Nrf2, cellular antioxidants such as heme oxygenase-1 (HO-1) and NADPH quinone oxidoreductase 1 (NQO1) activities, thus, in turn, prevents the secretion of pro-inflammatory mediators. The SFN down-regulates TMPRSS2 levels and results in the protection against infection. Available reports elucidated that the Nrf2 negatively regulates the TMPRSS2 (Meyer and Jaspers, 2015). Kesic and colleagues demonstrated that the SFN exerts protective effects against respiratory viruses and reduces the IAV entry into respiratory epithelial cells probably as a result of a reduction in TMPRSS2 expression (Kesic et al., 2011).

In addition to the possible androgen receptor-targeted treatments to modify the expression of the TMPRSS2, impairing its protease activity would be an alternative approach. Camostat mesylate, known as FOY 305, is clinically used to treat chronic pancreatitis. It could protect cultured lung epithelia and mice from infection with the H1N1 influenza virus (Bahgat et al., 2011). Shirato et al. report that the treatment with camostat (a single dose) could sufficiently hamper the MERS-CoV entry into Calu-3 cells (a lung-derived cell line) and possibly into the lung (Shirato et al., 2013). Moreover, the viral multistep growth was significantly repressed and virus-induced host cell death was hindered. They concluded that the camostat-inhibited TMPRSS2 or other serine proteases may determine virus pathogenesis and tropism in the lung (Shirato et al., 2013). It is also reported that the SARS-CoV pathogenesis and spread can be efficiently prohibited by camostat (Zhou et al., 2015). This drug can target the TMPRSS2 protease and reduce the replication rate of SARS-CoV-2 (Hoffmann et al., 2020).

Bromhexine hydrochloride (BRH) is a TMPRSS2 inhibitor that can attenuate metastasis in prostate cancer mice models (Lucas et al., 2014). Being an FDA-approved drug in mucolytic cough suppressants with no significant adverse effects, it can effectively be used against coronavirus infections (Barzegar et al., 2020; Wang et al., 2020c; Fu et al., 2020; Tolouian et al., 2020). In this regard, Li et al. conducted a clinical pilot study on Chinese patients to evaluate the beneficial effects of BRH tablets in moderate COVID-19 treatment. Their findings illustrated that BRH enhanced chest computed tomography (CT), the need for oxygen therapy, and the discharge rate within 20 days (Irham et al., 2020). Nafamostat— an anticoagulant- is another drug that can inhibit the activity of the TMPRSS2, so, it can reduce the viral entrance and block MERS-CoV infection in vitro (Yamamoto et al., 2016). Recently, evidence from the latest studies showed the advantages of nafamostat in COVID-19 patients (Asakura and Ogawa, 2020; Hoffmann et al., 2020d). A case study performed on three elderly COVID-19 patients in South Korea demonstrated
that nafamostat administration leads to disease prevention through regulating the complement cascade and blocking DIC. Furthermore, it may inhibit virus invasion by impeding virus fusion on the cell membrane (Jang and Rhee, 2020). Altogether, the TMPRSS2 has potential therapeutic benefits against respiratory coronavirus infections. Plasminogen activator inhibitor-1 (PAI-1) is an effective membrane-anchored serine protease inhibitor. It can inhibit TMPRSS2-mediated hemagglutinin cleavage and repress the influenza virus in animals.

Mc Cord et al. (2020) discovered that the PB125 could be used as a therapeutic agent in COVID-19 patients, evidenced by upregulated LIF, suppressed inflammatory responses, inhibited TMPRSS2 gene expression directly or by prevention of PAI-1, encoded by the SERPINE1 (Dittmann et al., 2015) and increased Nrf2 activity by HDAC5 downregulation (Hu et al., 2019). In the human airway epithelial cell line, aprotinin and synthetic inhibitors of the TMPRSS2 could inhibit the replication of SARS-CoV-2. Combining several inhibitors of the TMPRSS2 could result in a more effective antiviral activity against the virus than a single serine protease inhibitor. The top 12 natural compounds that significantly can interact with the active sites of the TMPRSS2 are reviewed by Rahman et al. (202).

**Furin Inhibitors**

Unlike the TMPRSS2, furin and furin-like enzymes are essential for several pathways and normal development, therefore, its prolonged blockade may lead to some adverse and toxic effects (Hasan et al., 2020). However, a brief furin inhibition may exert a therapeutic benefit and be tolerated (Sarac et al., 2002).

To achieve satisfactory outcomes, a mixture of protease inhibitors would be required. The combination of furin inhibitors that target different proteases of SARS-CoV-2 might be an interesting therapeutic strategy (Wu et al., 2020b). Moreover, a combined administration of furin and the TMPRSS2 inhibitors can be used to target both of these proteases. Evidence shows that the combination of furin inhibitor MI-1851 with several TMPRSS2 inhibitors (MI-1900 and MI-432) could produce more effective antiviral activity against the newly emerged virus than any single serine protease inhibitor (Bestle et al., 2020a).

**Cathepsin Inhibitors**

The inhibitors of cathepsin B (CA-074), cathepsin L (SID 26681509), and calpain (E64D) were tested in HEK 293/hACE2 cells. The findings illustrated that 293/hACE2 cells treated with E64D, had a decreased entry of the SARS-CoV2 S pseudovirions (about 92.5%), which in turn highlight the role of at least one of the calpain or cathepsins for SARS-CoV-2 entry. Moreover, treatment with cathepsin L inhibitor by 76% reduced the entry of SARS-CoV-2 S pseudovirions, indicating the probable role of lysosomal cathepsin L in priming SARS-CoV-2 S protein in 293/hACE2 cells. However, cathepsin B inhibitor showed no significant effects on virus entry (Korkmaz et al., 2020; Sahebnasagh et al., 2020). Applying both the E-64D and camostat mesylate results in a complete inhibition of SARS-CoV-2 S protein-driven entry into Vero-TMPRSS2 cells and Caco-2 cells which proposed that both cathepsins B, L and TMPRSS2 is required for priming cells (Hoffmann et al., 2020a). The inhibition of cathepsin L offers two possible steps for the coronavirus infection, blocking virus entry on the host cell surface and viral material release and replication inside the host cell endosomes (Liu et al., 2020).

**Other Protease Inhibitors**

Utilizing sivelestat- a neutrophil elastase inhibitor- leads to acute lung injury (ALI) alleviation via enhancing alveolar epithelium, vascular endothelium injuries and reducing vascular permeability induced by neutrophils. Though it can be considered as a novel treatment approach in controlling ALI/ARDS or coagulopathy in COVID-19 patients (Sahebnasagh et al., 2020). The suppression of plasmin activity by antiproteases may prevent SARS-CoV-2 entry into respiratory cells and alleviate the clinical outcomes of COVID-19 patients (Ji et al., 2020).

**CLINICAL TRIALS**

Ansarin et al. for the first time performed an open-label randomized clinical trial, to investigate the efficacy of early administration of bromhexine in patients with COVID-19 pneumonia in Tabriz, Iran. The oral administration of bromhexine results in a significant reduction in ICU admissions, intubation and mortality in the treated group in comparison to the control group. Furthermore, bromhexine treatment exhibited an improvement in C-reactive protein (CRP), lactate dehydrogenase (LDH), and neutrophil/lymphocyte ratio (NLR) levels within two weeks when compared to the control group. However, their results demonstrated that there was no significant difference in the length of hospital stay among treated and control groups (Ansarin et al., 2020).

Li and colleagues conducted an open-label randomized controlled pilot study to examine the efficacy and safety of bromhexine hydrochloride in the treatment of moderate COVID-19. The oral administration of bromhexine hydrochloride (for 14 consecutive days) improved chest computed tomography, a need for oxygen therapy, and discharge rate in 20 days. Nevertheless, their data were not statistically significant (Shang et al., 2020).

Hofmann-Winkler et al. evaluated the efficacy of camostat mesylate in critically ill COVID19 patients with organ failure admitted in ICU of University Hospital Göttingen, Germany. Their findings revealed that the Sepsis-related Organ Failure Assessment score declined in the camostat mesylate-treated group; however, in the hydroxychloroquine group it remained high. Besides, camostat mesylate administration results in a reduction of disease severity, inflammatory markers and amelioration of oxygenation within 8 days in comparison to patients receiving hydroxychloroquine (Hofmann-Winkler et al., 2020). Doi et al. reported the efficacy of nafamostat...
mesylate in combination with favipiravir in critically ill COVID-19 patients admitted to the ICU at The University of Tokyo Hospital. Nafamostat therapy targets the virus entry in host epithelial cells and impedes intracellular coagulopathy (Doi et al., 2020).

CONCLUSION

Unique landscapes of SARS-CoV-2 entry are low frequency of RBD standing up that is implicated for immune evasion; moreover, its RBD has a high binding affinity to hACE2 that provides an efficient entry. Finally, the pre-activation of the spike by furin enhances viral entry into some cells. All these features compensate for SARS-CoV-2′ hidden RBD and possibly permit the virus to preserve an effective cell entry yet evading immune surveillance. All these characteristics may be responsible for the viral widespread.

Among different host factors that are involved in the entrance of SARS-CoV-2, transcriptional inhibition of the TMPRSS2 seems to be a hopeful strategy. As with scientific coincidences, our TMPRSS2 insights are obtained from cancer research. TMPRSS2 inhibitor could decrease prostate cancer severity in a mouse model. Additional evidence for effective inhibition of the TMPRSS2 comes from a report indicated that aprotinin could successfully inhibit influenza virus infections (Zhirnov, 1987), although the HA activating protease TMPRSS2 was unknown at that time—thereafter identified by Böttcher et al. (2006). Since the TMPRSS2 is vital for SARS-CoV-2 entry into the host cells, we propose that the same TMPRSS2 inhibitors may decrease or prevent SARS-CoV-2 infection and can be an affordable medicine in blocking the TMPRSS2. The results of our clinical trial supported this idea and indicated that the administration of bromhexine is promising in the early stage of the COVID-19. It should be noted that transcriptional inhibition of the TMPRSS2 may not be destructive since it seems the TMPRSS2 has no important role in any organ and its blockade does not compromise normal development and homeostasis in the host. However, there are conflicting data on the role of TMPRSS2 blocking in the prevention and/or treatment of COVID-19. Well-designed and large-scale clinical trials are required to shed light on this issue in clinical practice.

AUTHOR'S CONTRIBUTION

MA and SZV developed the concept and designed the study. SMHK and YRS did systematic search and prepared the first draft. All authors participated in the revising of the manuscript before submission.

REFERENCES

Afar, D. E., Vivanco, I., Hubert, R. S., Kuo, J., Chen, E., Saffran, D. C., et al. (2001). Catalytic Cleavage of the Androgen-Regulated TMPRSS2 Protease Results in its Secretion by Prostate and Prostate Cancer Epithelia. Cancer Res. 61 (4), 1686–1692.

Al-Horani, R. A. (2020). Potential Therapeutic Roles for Direct Factor Xa Inhibitors in Coronavirus Infections. Am. J. Cardiovasc. Drugs 20, 525–533. doi:10.1007/s40256-020-00438-6

Ansarin, K., Tolouian, R., Ardalan, M., Taghizadieh, A., Varshochi, M., Teimouri, S., et al. (2020). Effect of Bromhexine on Clinical Outcomes and Mortality in COVID-19 Patients: A Randomized Clinical Trial. Virol. J. 17 (1), 209–215. doi:10.34172/bi.2020.27

Antalis, T. M., Bugge, T. H., and Wu, Q. (2011). Membrane-anchored Serine Proteases in Health and Disease. Prog. Mol. Biol. Transl. Sci. 99, 1–50. doi:10.1016/b978-0-12-385504-6.00001-4

Antalis, T. M., Buzza, M. S., Hodge, K. M., Hooper, J. D., and Nettel-Arnott, S. (2010). The Cutting Edge: Membrane-Anchored Serine Protease Activities in the Pericellular Microenvironment. Biochem. J. 428 (3), 325–346. doi:10.1042/bj20100046

Asakura, H., and Ogawa, H. (2020). Potential of Heparin and Nafamostat Combination Therapy for COVID-19. J. Thromb. Haemost. 18 (6), 1521–1522. doi:10.1111/jth.14858

Ashour, H. M., Elkhathat, W. F., Rahman, M. M., and Elshabrawy, H. A. (2020). Insights into the Recent 2019 Novel Coronavirus (SARS-CoV-2) in Light of Past Human Coronavirus Outbreaks. Pathogens 9 (3), 186. doi:10.3390/pathogens9030186

Bahgat, M. M., Blazejewska, P., and Schughart, K. (2011). Inhibition of Lung Serine Proteases in Mice: a Potentially New Approach to Control Influenza Infection. Virol. J. 8, 27. doi:10.1186/1743-422x-8-27

Bai, X., Hippensteel, J., Leavitt, A., Maloney, J. P., Beckham, D., Garcia, C., et al. (2020). Hypothesis: Alpha-1-Antitrypsin Is a Promising Treatment Option for COVID-19. Med. Hypotheses 146, 110394. doi:10.1016/j.mehy.2020.110394

Barzegar, A., Ghadipasha, Masoud., Rezaei, Nima., Forouzesh, Mehdi., and Valizadeh, Rohollah. (2020). New hope for Treatment of Respiratory Involvement Following COVID-19 by Bromhexine. Pharmacol. Ther. 28, 98–108. doi:10.34172/pn.2021.11

Benton, D. J., Wrobel, A. G., Xu, P., Roustan, C., Martin, S. R., Rosenthal, P. B., et al. (2020). Receptor Binding and Priming of the Spike Protein of SARS-CoV-2 for Membrane Fusion. Nature 588 (7837), 327–330. doi:10.1038/s41586-020-2772-0

Bertram, S., Dijkman, R., Habjan, M., Heurich, A., Gierer, S., Glowacka, I., et al. (2013). TMPRSS2 Activates the Human Coronavirus 229E for Cathepsin-independent Host Cell Entry and Is Expressed in Viral Target Cells in the Respiratory Epithelium. J. Virol. 87 (11), 6150–6160. doi:10.1128/jvi.03372-12

Böttcher, E., Heindl, M. R., Limburg, H., Van Lam van, T., Pilgram, O., Moulton, H., et al. (2020). TMPRSS2 and Furin Are Both Essential for Proteolytic Activation of SARS-CoV-2 in Human Airway Cells. Life Sci. Alliance 3 (9), e202000786. doi:10.26508/lsa.202000786

Bojkova, D. (2020). SARS-CoV-2 and SARS-CoV Differ in Their Cell Tropism and Drug Sensitivity Profiles. New York: Cold Spring Harbor. doi:10.1101/2020.04.03.024257

Böttcher, E., Matrosovich, T., Beyerle, M., Klussmann, J., Garten, W., and Matrosovich, M. (2006). Proteolytic Activation of Influenza Viruses by Serine Proteases TMPRSS2 and HAT from Human Airway Epithelium. J. Virol. 80 (19), 9896–9898. doi:10.1128/JVI.01118-06

Chandran, K., Sullivan, N. J., Felbor, U., Whelan, S. P., and Cunningham, J. M. (2005). Endosomal Proteolysis of the Ebola Virus Glycoprotein Is Necessary for Infection. Science 308 (5728), 1643–1645. doi:10.1126/science.1110656

Chen, Z., Song, fmn., Li, fmn., Xie, fmn., Guo, fmn., Su, fmn., et al. (2019). Androgen Receptor-Activated Enhancers Simultaneously Regulate Oncogene TMPRSS2 and IncRNA PRCAT38 in Prostate Cancer. Cells 8 (8), 864. doi:10.3390/cells8080864

Cheng, Y.-W., Chao, T.-L., Li, C.-L., Chiu, M.-F., Kao, H.-C., Wang, S.-H., et al. (2020). Furin Inhibitors Block SARS-CoV-2 Spike Protein Cleavage to Suppress
Host Serine Proteases and COVID-19

Virus Production and Cytotoxic Effects. *Cell Rep.* 33 (2), 108254. doi:10.1016/j.celrep.2020.108254

Cheng, Z., Zhou, J., To, K. K.-W., Chu, H., Li, C., Wang, D., et al. (2015). Identification of TMPRSS2as a Susceptibility Gene for Severe 2009 Pandemic A(H1N1) Influenza and A(H7N9) Influenza. *J. Infect. Dis.* 212 (8), 1214–1221. doi:10.1093/infdis/jiv246

Coutard, B., Valle, C., de Lamballerie, X., Canard, B., Seidah, N. G., and Decroly, E. (2020). Cleavage of Furin-like Cleavage Site Absent in CoV of the Same Clade. *Virology* 551, 263. doi:10.1016/j.virol.2020.05.072

Kim, J., C. Y., Kolitz, S., Funt, J., Escalante Chong, R., Barrett, S., Zeskind, B., et al. (2020). KISS1R Has a Critical Role in SARS-CoV-2 Entry and Is Blocked by a Clinically Proven Protease Inhibitor. *Cell 181*, 271–280. doi:10.1016/j.cell.2020.02.052

Hoffmann, M., Kleine-Weber, S., Müller, M. A., Drosten, C., and Pöhlmann, S. (2020). Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19. *Antimicrob. Agents Chemother.* 64 (6), e00754. doi:10.1128/AAC.00754-20

Hoffmann, M., Kleine-Weber, S., Müller, M. A., Drosten, C., and Pöhlmann, S. (2020). Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19. *Antimicrob. Agents Chemother.* 64 (6), e00754. doi:10.1128/AAC.00754-20

Kirkmaier, B., Lesner, A., Marchand-Adam, S., Moss, C., and Jenne, D. E. (2020). Lung Protection by Cathepsin C Inhibition: A New Hope for COVID-19 and Respiratory Syndrome Coronavirus Spike Protein. *J. Virol.* 88 (2), 1293–1307. doi:10.1128/jvi.02202-13

Heurich, A., Hofmann-Winkler, H., Gierer, S., Liepold, T., Jahn, O., and Pöhlmann, S. (2014). TMPRSS2 and ADAM17 Cleave ACE2 Differentially and Only Proteolysis by TMPRSS2 Drives Entry by the Severe Acute Coronavirus Spike Protein. *J. Virol.* 88 (2), 1293–1307. doi:10.1128/jvi.02202-13

Hoffmann, M., Kleine-Weber, S., Krüger, N., Herrler, T., Erichsen, S., et al. (2020). SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. *Cell 181*, 271–280. doi:10.1016/j.cell.2020.02.052

Oiwat-Yoshikawa, N., Okamura, T., Shimizu, Y., Hasegawa, H., Takeda, M., and Nagata, N. (2019). TMPRSS2 Contributes to Virus Spread and Immunopathology in the Airways of Murine Models after Coronavirus Infection. *J. Virol.* 93 (6), e01818. doi:10.1128/JVI.01818-18

Iwata-Yoshikawa, N., Okamura, T., Shimizu, Y., Hasegawa, H., Takeda, M., and Nagata, N. (2019). TMPRSS2 Contributes to Virus Spread and Immunopathology in the Airways of Murine Models after Coronavirus Infection. *J. Virol.* 93 (6), e01818. doi:10.1128/JVI.01818-18

Iwata-Yoshikawa, N., Okamura, T., Shimizu, Y., Kotani, O., Sato, H., Sekimukai, H., et al. (2019). Acute Respiratory Infection in Human Dipeptidyl Peptidase 4-Transgenic Mice Infected with Middle East Respiratory Syndrome Coronavirus. *J. Virol.* 93 (6), e01818. doi:10.1128/JVI.01818-18

Jang, S., and Rhee, J.-Y. (2020). Three Cases of Treatment with Nafamostat in Elderly Patients with COVID-19 Pneumonia Who Need Oxygen Therapy. *Int. J. Infect. Dis.* 96, 500. doi:10.1016/j.ijid.2020.05.072

Ji, H.-L., Zhao, R., Matsalou, S., and Madath, M. A. (2020). Elevated Plasmin(ogen) as a Common Risk Factor for COVID-19 Susceptibility. *Physiol. Rev.* 100 (3), 1065–1075. doi:10.1152/physrev.00013.2020

Kim, J. C. Y., Kolitz, S., Funt, J., Escalante Chong, R., Barrett, S., Zeskind, B., et al. (2020). Advanced Bioinformatics Rapidly Identifies Existing Therapeutics for Patients with Coronavirus Disease-2019 (COVID-19). *J. Transl Med.* 18, 257. doi:10.1186/s12967-020-02430-9
ARMS? J. Med. Chem. 63 (22), 13258–13265. doi:10.1021/acs.jmedchem.0c00776

Lambertz, R. L. O., Gerhauser, I., Nehlmeier, I., Leist, S. R., Kollmus, H., Pöhlmann, S., et al. (2019). TMPRSS2 Knock-Out Mice Are Resistant to H10 Influenza A Virus Pathogenesis. J. Gen. Virol. 100 (7), 1073–1078. doi:10.1099/iov.0.001274

Lin, B., Ferguson, C., White, J. T., Wang, S., Vessella, R., True, L. D., et al. (1999). Prostate-localized and Androgen-Regulated Expression of the Membrane-Bound Serine Protease TMPRSS2. Cancer Res. 59 (17), 4180–4184.

Liu, T., Luo, S., Libby, P., and Shi, G.-P. (2020). Cathepsin L-Selective Inhibitors: A Potentially Promising Treatment for COVID-19 Patients. Pharmacol. Ther. 213, 107587. doi:10.1016/j.pharmthera.2020.107587

Lu, R., Zhao, X., Li, J., Niu, P., Yang, B., Wu, H., et al. (2020). Genomic Characterisation and Epidemiology of 2019 Novel Coronavirus: Implications for Virus Origins and Receptor Binding. The Lancet 395 (10224), 565–574. doi:10.1016/S0140-6736(20)30251-8

Luan, B., Huynh, T., Cheng, X., Lan, G., and Wang, H.-R. (2020). Targeting Proteases for Treating COVID-19. J. Proteome Res. 19 (11), 4316–4326. doi:10.1021/acs.jproteome.0c00340

Lucas, J. M., Heinleim, C., Kim, T., Hernandez, S. A., Malik, M. S., True, L. D., et al. (2014). The Androgen-Regulated Protease TMPRSS2 Activates a Proteolytic Cascade Involving Components of the Tumor Microenvironment and Promotes Prostate Cancer Metastasis. Cancer Discov. 4 (11), 1310–1325. doi:10.1158/2159-8290.cd-13-110

Lucas, J., True, L., Hawley, S., Matsumura, M., Morrissey, C., Vessella, R., et al. (2008). The Androgen-Regulated Type II Serine Protease TMPRSS2 Is Differentially Expressed and Mislocalized in Prostate Adenocarcinoma. J. Pathol. 215 (2), 118–125. doi:10.1002/path.2330

Mallapati, S. (2020). Why Does the Coronavirus Spread So Easily between People? Nature 579 (7798), 183. doi:10.1038/d41586-020-00660-x

Matsuyama, S., Nagata, N., Shirato, K., Kawase, M., Takeda, M., and Taguchi, F. (2010). Efficient Activation of the Severe Acute Respiratory Syndrome Coronavirus Spike Protein by the Transmembrane Protease TMPRSS2. J. Virol. 84 (24), 12658–12666. doi:10.1128/jvi.01542-10

Matsuyama, S., Nao, N., Shirato, K., Kawase, M., Saito, S., Takayama, I., et al. (2020). Enhanced Isolation of SARS-CoV-2 by TMPRSS2-Expressing Cells. Proc. Natl. Acad. Sci. USA 117 (13), 7001–7003. doi:10.1073/pnas.2005891117

McCord, J. M., Hybertson, B. M., Cota-Gomez, A., Geraci, K. P., and Gao, B. (2020). Nrf2 Activator PB125 as a Potential Therapeutic Agent against COVID-19. New York: Cold Spring Harbor. doi:10.1016/j.virol.2020.05.099788

Medcalf, R. L., Keragala, C. B., and Myles, P. S. (2020). Fibronilysis and COVID-19: A Plasmin Paradox. J. Thromb. Haemost. 18, 2118. doi:10.1111/jth.14960

Mei, Z., Gao, Hong-bin, Wu, Kai-bin, Liu, Ming-xiao, Liu, Chang, and Wang Xin-hong. (2020). Significant Expression of FURIN and ACE2 on Oral Epithelial Cells May Facilitate the Efficiency of 2019-nCov Entry. New York: Cold Spring Harbor. doi:10.1002/path.2395

Meyer, D., Stiefl, F., Hammami, M., Böttcher-Friebertshäuser, E., Garten, W., and Steinmetzer, T. (2013). Identification of the First Synthetic Inhibitors of the Type II Transmembrane Serine Protease TMPRSS2 Suitable for Inhibition of Influenza Virus Activation. Biochem. J. 452 (2), 331–343. doi:10.1042/ bj20130101

Meyer, J., and Jaspers, I. (2015). Respiratory Protease/antiprotease Balance Determines Susceptibility to Viral Infection and Can Be Modified by Nutritional Antioxidants. Am. J. Physiology-Lung Cell Physiol. 308 (12), L1189–L1201. doi:10.1152/ajplm.00208.2015

Nickols, N. G., and Dervan, P. B. (2007). Suppression of Androgen Receptor-Mediated Gene Expression by a Sequence-specific DNA-Binding Polyamide. Proc. Natl. Acad. Sci. 104 (25), 10418–10423. doi:10.1073/pnas.0704217104

Paniri, A., Hosseini, M. M., and Akhavan-Niazi, H. (2020). First Comprehensive Computational Analysis of Functional Consequences of TMPRSS2 SNPs in Susceptibility to SARS-CoV-2 Among Different Populations. J. Biomol. Struct. Dyn. 39, 1–18. doi:10.1080/07391102.2020.1767690

Paoloni-Giacobino, A., Chen, H., Peitsch, M. C., Rossier, C., and Antonarakis, S. E. (1997). Cloning of the TMPRSS2 Gene, Which Encodes a Novel Serine Protease with Transmembrane, LDLRA, and SRCR Domains and Maps to 21q22.3. Genomics 44 (3), 309–320. doi:10.1016/S0888-7543(97)80045-6
Song, H., Seddighzadeh, B., Cooperberg, M. R., and Huang, F. W. (2020). Expression of ACE2, the SARS-CoV-2 Receptor, and TMPRSS2 in Prostate Epithelial Cells. New York: Cold Spring Harbor. doi:10.1101/2020.04.24.056259

Thierry, A. R. (2020). Anti-protease Treatments Targeting Plasmin(ogen) and Neutrophil Elastase May Be Beneficial in Fighting COVID-19. *Physiol. Rev.* 100 (4), 1597–1598. doi:10.1152/physrev.00019.2020

Tolouian, R., Tolouian, A. C., and Ardalan, M. (2020). Blocking Serine Protease (TMPRSS2) by Bromhexine; Looking at Potential Treatment to Prevent COVID-19 Infection. *Marshall J. Med.* 6 (3). doi:10.33470/2379-9536.1286

Vankadari, N. (2020). Structural Interactions between Pandemic SARS-CoV-2 Spike Glycoprotein and Human Furin Protease. New York: Cold Spring Harbor.

Vargas-Alarcón, G., Posadas-Sánchez, R., and Ramirez-Bello, J. (2020). Variability in Genes Related to SARS-CoV-2 Entry into Host Cells (ACE2, TMPRSS2, TMPRSS11A, ELANE, and CTSL) and its Potential Use in Association Studies. *Life Sci.* 260, 118313. doi:10.1016/j.lfs.2020.118313

Wang, Q., Qiu, Y., Li, J. Y., Zhou, Z. J., Liao, C. H., and Ge, X. Y. (2020). A Unique Protease Cleavage Site Predicted in the Spike Protein of the Novel Pneumonia Coronavirus (2019-nCoV) Potentially Related to Viral Transmissibility. *Virologica Sinica* 35, 337–339. doi:10.1007/s12250-020-00212-7

Wang, X., Dhindsa, Ryan., Povysil, Gundula., Zoghbi, Anthony., Motelow, Joshua., Hostyk, Joseph., et al. (2020). Transcriptional Inhibition of Host Viral Entry Proteins as a Therapeutic Strategy for SARS-CoV-2. Basel, Switzerland: Preprints, 2020030360.

Wang, Y., Zhang, Y., Chen, X., Xue, K., Zhang, T., and Ren, X. (2020). Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets in Treating Pediatric COVID-19: A Protocol for Meta-Analysis and Systematic Review. *Medicine (Baltimore)* 99 (37). e22114. doi:10.1097/MD.0000000000022114

Wu, C., Zheng, M., Yang, Y., Gu, X., Yang, K., Li, M., et al. (2020). Furin: A Potential Therapeutic Target for COVID-19. *iScience* 23 (10), 101642. doi:10.1016/j.isci.2020.101642

Wu, F., Zhao, S., Yu, B., Chen, Y-M., Wang, W., Hu, Y., et al. (2020). Complete Genome Characterisation of a Novel Coronavirus Associated with Severe Human Respiratory Disease in Wuhan. New York: China. doi:10.1101/2020.01.24.919183

Xu, Z., Wang, Y., Xiao, Z. G., Zou, C., Zhang, X., Wang, Z., et al. (2018). Nuclear Receptor ERα and Transcription Factor ERG Form a Reciprocal Loop in the Regulation of TMPRSS2:ERG Fusion Gene in Prostate Cancer. *Oncogene* 37 (37), 6259–6274. doi:10.1038/s41388-018-0409-7

Yamamoto, M., Matsuyama, S., Li, X., Takeda, M., Kawaguchi, Y., Inoue, J.-i., et al. (2016). Identification of Nafamostat as a Potent Inhibitor of Middle East Respiratory Syndrome Coronavirus 5-Protein-Mediated Membrane Fusion Using the Split-Protein-Based Cell-Cell Fusion Assay. *Antimicrob. Agents Chemother.* 60 (11), 6532–6539. doi:10.1128/aac.01043-16

Yuan, Y., Cao, D., Zhang, Y., Ma, J., Qi, J., Wang, Q., et al. (2017). Cryo-EM Structures of MERS-CoV and SARS-CoV Spike Glycoproteins Reveal the Dynamic Receptor Binding Domains. *Nat. Commun.* 8, 15092. doi:10.1038/ncomms15092

Zang, R., Gomez Castro, M. F., McCune, B. T., Zeng, Q., Rothlauf, P. W., Sonnek, N. M., et al. (2020). TMPRSS2 and TMPRSS4 Promote SARS-CoV-2 Infection of Human Small Intestinal Enterocytes. *Sci. Immunol.* 5 (47), eabc3582. doi:10.1126/sciimmunol.abc3582

Zhang, J. (2020). Teicoplanin Potently Blocks the Cell Entry of 2019-nCoV. New York: Cold Spring Harbor.

Zhou, M.-M., Yang, W.-L., Yang, F.-Y., Zhang, L., Huang, W.-J., Hou, W., et al. (2021). Cathepsin L Plays a Key Role in SARS-CoV-2 Infection in Humans and Humanized Mice and Is a Promising Target for New Drug Development. *Sig Transduct Target. Ther.* 6 (1), 134. doi:10.1038/s41392-021-00558-8

Zhirnov, O. P. (1987). High protection of Animals Lethally Infected with Influenza Virus by Aprotinin-Rimantadine Combination. *J. Med. Virol.* 21 (2), 161–167. doi:10.1002/jmv.1890210208

Zhou, L., Niu, Z., Jiang, X., Zhang, Z., Zheng, Y., Wang, Z., et al. (2020). SARS-CoV-2 Targets by the pscrNA Profiling of ACE2, TMPRSS2 and Furin Proteases. *iScience* 23 (11), 101744. doi:10.1016/j.isci.2020.101744

Zhou, Y., Vedantham, P., Lu, K., Agudelo, J., Carrion, R., Nunneley, J. W., et al. (2015). Protease Inhibitors Targeting Coronavirus and Filovirus Entry. *Antiviral Res.* 116, 76–84. doi:10.1016/j.antiviral.2015.01.011

Zumla, A., Chan, J. F. W., Azhar, E. I., Hui, D. S. C., and Yuen, K.-Y. (2016). Coronavirus - Drug Discovery and Therapeutic Options. *Nat. Rev. Drug Discov.* 15 (5), 327–347. doi:10.1038/nrd.2015.37

Zununi Vahed, S., Ghiasvand, S., Tolouian, R., Noshad, H., Tolouian, A., Mohajel Shoja, M., et al. (2020). The Footprint of Androgen Sensitive Serine Protease (TMPRSS2) in Gender Mortality with COVID-19. *Immunopathol Persa* 6 (2), e27. doi:10.34172/ipp.2020.27

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

**Copyright © 2021 Rahbar Saadat, Hoseiniyani Khatibi, Zununi Vahed and Ardalan.** This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.